Literature DB >> 7516041

Analysis of plasma and hematoma lipids related to choline glycerophospholipid in patients with chronic subdural hematoma.

Y Hirashima1, T Nagahori, M Nishijima, S Endo, A Takaku, Y Nakagawa.   

Abstract

The levels of platelet-activating factor (PAF) and lipid metabolites related to choline glycerophospholipid were measured in the plasma and hematoma samples obtained from patients with chronic subdural hematoma. The ratio of lyso-choline glycerophospholipids (lysoPC) to choline glycerophospholipids (PC) in hematoma correlated with the interval between the onset of symptoms and surgery. PC and lysoPC fatty acyl moieties in plasma and hematoma were essentially similar. These results suggest that the lysoPC to PC ratio in hematoma can determine the age of the chronic subdural hematoma, and that the origin of hematoma may be circulating blood. The levels of PAF in the plasma of chronic subdural hematoma patients were significantly greater than in healthy volunteers. PAF may be involved in the enlargement of chronic subdural hematoma.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7516041     DOI: 10.2176/nmc.34.131

Source DB:  PubMed          Journal:  Neurol Med Chir (Tokyo)        ISSN: 0470-8105            Impact factor:   1.742


  3 in total

1.  Outcome of contemporary surgery for chronic subdural haematoma: evidence based review.

Authors:  R Weigel; P Schmiedek; J K Krauss
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-07       Impact factor: 10.154

2.  Platelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers.

Authors:  Y Hirashima; S Endo; N Hayashi; K Karasawa; S Nojima; A Takaku
Journal:  Acta Neurochir (Wien)       Date:  1995       Impact factor: 2.216

Review 3.  Management of Subdural Hematomas: Part II. Surgical Management of Subdural Hematomas.

Authors:  Elena I Fomchenko; Emily J Gilmore; Charles C Matouk; Jason L Gerrard; Kevin N Sheth
Journal:  Curr Treat Options Neurol       Date:  2018-07-18       Impact factor: 3.598

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.